[Zurück zur
Trefferliste]
 

Does Oral Implant Design Affect Marginal Bone Loss? Results of a Parallel-Group Randomized Controlled Equivalence Trial.

Universitätsklinikum

Autoren:
Spies BC, Bateli M, Ben Rahal G, Christmann M, Vach K, Kohal RJ
Titel:
Does Oral Implant Design Affect Marginal Bone Loss? Results of a Parallel-Group Randomized Controlled Equivalence Trial.
Kurzzitat:
Spies BC, Bateli M, Ben Rahal G, Christmann M, Vach K, Kohal RJ: Does Oral Implant Design Affect Marginal Bone Loss? Results of a Parallel-Group Randomized Controlled Equivalence Trial. Biomed Res Int, 2018; 2018 (online): 8436437. : https://doi.org/10.1155/2018/8436437
Publikationstyp:
Originalarbeiten in wissenschaftlichen Fachzeitschriften
Abstract:
Objective: To test whether or not the modified design of the test implant (intended to increase primary stability) has an equivalent effect on MBL compared to the control. Methods: Forty patients were randomly assigned to receive test or control implants to be installed in identically dimensioned bony beds. Implants were radiographically monitored at installation, at prosthetic delivery, and after one year. Treatments were considered equivalent if the 90% confidence interval (CI) for the mean difference (MD) in MBL was in between -0.25 and 0.25 mm. Additionally, several soft tissue parameters and patient-reported outcome measures (PROMs) were evaluated. Linear mixed models were fitted for each patient to assess time effects on response variables. Results: Thirty-three patients (21 males, 12 females; 58.2 ± 15.2 years old) with 81 implants (47 test, 34 control) were available for analysis after a mean observation period of 13.9 ± 4.5 months (3 dropouts, 3 missed appointments, and 1 missing file). The adjusted MD in MBL after one year was -0.13 mm (90% CI: -0.46-0.19; test group: -0.49; control group: -0.36; p = 0.507). Conclusion: Both implant systems can be considered successful after one year of observation. Concerning MBL in the presented setup, equivalence of the treatments cannot be concluded. Registration: This trial is registered with the German Clinical Trials Register (ID: DRKS00007877).
URL
https://doi.org/10.1155/2018/8436437
Kontakt:
Institut für Medizinische Biometrie und Statistik

Stefan-Meier-Strasse 26
79104 Freiburg

Tel: 0761 203 6662
Fax: 0761 203 6680
Email: sec@imbi.uni-freiburg.de
http://www.imbi.uni-freiburg.de
Forschungsbericht der Abteilung für das Jahr 2018